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Abstract 
Purpose. A survey in 2015 identified a high level of eye care practitioner concern about 
myopia with a reported moderately high level of activity, but the vast majority still prescribed 
single vision interventions to young myopes. This research aimed to update these findings 4 
years later. 
Methods. A self-administrated, internet-based questionnaire was distributed in eight 
languages, through professional bodies to eye care practitioners globally. The questions 
examined: awareness of increasing myopia prevalence, perceived efficacy of available 
strategies and adoption levels of such strategies, and reasons for not adopting specific 
strategies. 
Results. Of the 1,336 respondents, concern was highest (9.0 ± 1.6; p < 0.001) in Asia and 
lowest (7.6 ± 2.2; p < 0.001) in Australasia. Practitioners from Asia also considered their 
clinical practice of myopia control to be the most active (7.7 ± 2.3; p < 0.001), the North 
American practitioners being the least active (6.3 ± 2.9; p < 0.001). Orthokeratology was 
perceived to be the most effective method of myopia control, followed by pharmaceutical 
approaches and approved myopia control soft contact lenses (p < 0.001). Although significant 
intra-regional differences existed, overall, most practitioners did not consider single-vision 
distance under-correction to be an effective strategy for attenuating myopia progression 
(79.6%), but prescribed single vision spectacles or contact lenses as the primary mode of 
correction for myopic patients (63.6 ± 21.8%). The main justifications for their reluctance to 
prescribe alternatives to single vision refractive corrections were increased cost (20.6%) and 
inadequate information (17.6%).  
Conclusions.  While practitioner concern about myopia and the reported level of activity have 
increased over the last 4 years, the vast majority of eye care clinicians still prescribe single 
vision interventions to young myopes. With recent global consensus evidence-based 
guidelines having been published, it is hoped that this will inform the practice of myopia 
management in future. 
Keywords:  myopia control; myopia progression; myopia management; orthokeratology; 
global; attitudes  
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Introduction 
Due to the escalating global incidence of myopia, perpetual improvement in the 
evidence-based understanding of its vision risks and associated management remains 
essential. Holden et al. [1] projected myopia to affect half of the world’s population by 2050 
and with a propensity to become the leading cause for irreversible blindness. Deeming it a 
public health concern worldwide, The International Myopia Institute (IMI) released white 
papers (available online: https://www.myopiainstitute.org/imi-white-papers.html) synthesizing 
the latest and complete knowledge surrounding myopia across seven expert committees, 
including: Myopia Control Reports Overview and Introduction;[2] Defining and Classifying 
Myopia;[3] Experimental Models of Emmetropization and Myopia;[4] Myopia Genetics;[5] 
Interventions for Myopia Onset and Progression;[6] Clinical Myopia Control Trials and 
Instrumentation;[7] Industry Guidelines and Ethical Considerations for Myopia Control;[8] 
Clinical Myopia Management Guidelines.[9]  
               
During the past two decades, research in the field of myopia has expanded, but 
global agreement on guidelines for an optimum and standardized treatment regimen is still 
limited. Similarly, reported practitioner perception in the literature is scarce. A survey by Jung 
et al. [10] noted that most Korean ophthalmologists preferred to prescribe full cycloplegic 
spectacle refraction for childhood myopia control, followed by orthokeratology and spectacle 
undercorrection, whilst atropine was mostly considered ineffective. An international 
perspective,[11] solely focused on the prescribing trends of pediatric ophthalmologists 
reported: 57% of the 940 respondents routinely engaged in myopia control, but a lack of 
consensus remained on when to initiate treatment; the main precursor for treatment was 
myopia progression of ≥ 1 D/year; 70% prescribed eye drops of which atropine 0.01% 
accounted for 63.4%; 86% recommended increased time spent outdoors, whilst 60.2% and 
63.9% advised less screen viewing and smartphone use respectively. From the survey 
conducted in 2015, Wolffsohn et al. [12] reported that despite the high concern and activity 
over myopia progression and control respectively, most eye care practitioners worldwide 
prescribed single vision spectacles and contact lenses. This paper provides an update of 
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these attitudes and trends toward myopia management strategies in clinical practice four 
years later.   
 
Method 
A self-administered, internet-based cross-sectional survey in eight languages (Chinese, 
English, French, German, Italian, Portuguese, Russian and Spanish) was distributed using 
software SurveyMonkey (Palo Alto, California, USA) through various professional bodies 
across the world to reach eye care professionals (optometrists, dispensing opticians, 
ophthalmologists and others) globally. The survey matched the 2015 version (Wolffsohn et 
al., 2016) comprising of nine questions relating to the self-reported clinical management 
behaviours of practitioners for progressive myopia and practitioner’s current opinions on 
myopia related clinical care including: 
• level of concern about the increasing frequency of paediatric myopia in their 
clinical practice (rated as ‘Not at all,’ to ‘extremely,’ on a 10 point scale) 
• perceived effectiveness, defined as the expected level of reduction in 
childhood myopia progression of a range of myopia control options (rated as 
a percentage from 0 to 100%) 
• how active they would consider their clinical practice in the area of myopia 
control (rated as ‘Not at all,’ to ‘fully,’ on a 10 point scale) 
• frequency of prescribing different myopia correction options for progressive / 
young myopes during a typical month  
• minimum age a patient would need to be for them to consider myopia control 
options (assuming average handling skills and child/parent motivation) 
• minimum amount of myopia that would need to be present to consider myopia 
control options (specified in half dioptre steps) 
• minimum level of myopia progression (dioptres/year) that would prompt a 
practitioner to specifically adopt a myopia control approach (specified in 
quarter dioptre steps) 
• frequency of adopting single vision under-correction as a strategy to slow 
myopia progression (reported as ‘no,’ ‘sometimes,’ or ‘always’) 
• if they had only ever fitted single vision spectacles/contact lenses for myopic 
patients, what had prevented them (multiple options could be selected) from 
prescribing alternative refractive correction methods; options consisted of: 
o They don’t believe that these are any more effective 
o The outcome is not predictable 
o Safety concerns 
o Cost to the patient makes them uneconomical 
o Additional chair time required 
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o Inadequate information / knowledge 
o Benefit / risk ratio 
o Other 
 
There was an option to add further comments to each of the questions and the topic as a 
whole. Voluntary participation in the survey, following an explanation of the research, was 
anonymous, however, respondents were asked to provide basic demographic information 
about themselves (years of being qualified and everyday working environment). The data 
was collected between October 2018 and April 2019. 
 
Statistical Analysis 
Statistical analysis was conducted with SPSS (v21 IBM, New York, USA). Only complete 
surveys were analysed. Median, mean and standard deviations were calculated for each 
question response, with the results grouped by continent (Asia, Australasia, Europe, North 
America and South America) and countries within a continent where response rate allowed 
(n ≥ 30), with Kruskal-Wallis tests applied to determine statistical difference (taken as p < 





The total number of 1,336 complete survey responses were received, with the distribution by 
continent being: Africa 13 (not included in further analysis), Asia 202, Australasia 79; Europe 
717; Middle East 5 (not included in further analysis), North America 147; and South America 
173. Country specific responses could be extracted from: 
• Europe: Germany (n=68), Italy (n = 102), Netherlands (n = 40) Portugal (n = 76), 
Russia (n=78), Spain (n = 173) and UK/EIRE (n = 78) 
• Asia: China (n = 37), Hong Kong (n = 59) and India (n = 30) 
• North America; Canada (n = 47) and USA (n = 90) 
Of the study participants, 72.5% (n=968) were optometrists, 19.6% (n = 262) were 
ophthalmologists, 6.7% (n = 90) were contact lens opticians and 1.2% (n = 16) were other 
types of eye care specialists. The principal working environment for 90.7% was in clinical 
practice (n = 1,212), 5.1% worked in academia (n = 68), 2.1% worked within industry (n = 
29) and 2.1% (n = 29) worked in other environments. However, all study participants were 
registered eye care practitioners. The median number of years qualified was the 11-20 year 
category, with a normal distribution.   
 
Self-reported concern about the increasing frequency of paediatric myopia (Figure 1) 
Practitioners’ concern about the increasing frequency of paediatric myopia in their practices 
was highest (9.0 ± 1.6; p < 0.001) in Asia and lowest (7.6 ± 2.2; p < 0.001) in Australasia 
among the surveyed continents, with similar levels across Europe (8.0 ± 2.2; p < 0.001), 
North America (7.9 ± 2.1; p < 0.001) and South America (8.5 ± 2.2; p < 0.001). In Asia, 
Chinese practitioners were more concerned (9.5 ± 1.2; p < 0.001) than those in Hong Kong 
(8.7 ± 1.4; p < 0.001) or India (8.9 ± 1.3; p < 0.001). In Europe, practitioners from Russia (8.7 
± 1.9; p < 0.001), Portugal (8.7 ± 2.0; p < 0.001) and Spain (8.5 ± 1.9; p < 0.001) were most 
concerned, followed by Italy (7.8 ± 2.2; p < 0.001) and the UK/EIRE (7.5 ± 2.5; p < 0.001), 
with lowest concern in the Netherlands (7.1 ± 2.3; p < 0.001) and Germany (6.4 ± 2.3; p < 
0.001). In North America, practitioners from the USA (8.1 ± 2.0; p < 0.001) were more 
concerned than their Canadian neighbours (7.5 ± 2.2; p < 0.001). 
7 
 
Figure 1:  Level of practitioner concern (rated from 0-10) regarding the perceived 
increasing frequency of paediatric myopia in their practice for practitioners 
located in different continents. N=1,336. Box = 1 SD, line = median and 
whiskers 95% confidence interval. 
 
Perceived effectiveness of myopia control options (Table 1) 
Overall, orthokeratology was perceived by practitioners to be the most effective method of 
myopia control, followed by pharmaceutical approaches and approved myopia control soft 
contact lenses. The least effective perceived methods were single vision distance under-
correction and single vision spectacles, as well as single vision soft contact lenses and 
refractive surgery options. These findings were largely consistent across all continents with 
some variations: practitioners from South America held the lowest relative consideration 
regarding the most effective perceived methods, whilst practitioners from Asia, Europe, and 
South America held the highest relative consideration for the least effective perceived 
methods (p < 0.001). Moreover, the single vision spectacles modality was considered the 7th 
least effective out of the 12 survey choices in South America (p < 0.001). Practitioners from 
Asia considered bifocals and progressive addition (PALs) lenses to be relatively more 
effective for reducing childhood myopia progression compared with practitioners from all 
other continents (p < 0.001). Practitioners from Australasia and North America perceived 
single vision distance under-correction, single vision spectacles, rigid gas permeable (RGP) 
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and single vision soft contact lenses, refractive surgery, and increased time outdoors as less 
effective than practitioners from other continents (p < 0.001).  
 
Within Asia, Chinese practitioners generally held the highest relative consideration for most 
myopia control options, whereas practitioners from Hong Kong held the least overall 
perceived effectiveness for most myopia control options (p < 0.001). Similar effectiveness 
among practitioners from China, Hong Kong, and India was perceived for multifocal and 
approved myopia control soft contact lenses, as well as orthokeratology and pharmaceutical 
modalities (p < 0.001). Within Europe, the Netherlands generally held the lowest relative 
consideration for most myopia control options, whereas practitioners from Portugal, Russia, 
and Spain held the highest overall perceived effectiveness for most myopia control options 
(p < 0.001). Spanish practitioners perceived approved myopia control soft contact lenses 
and orthokeratology as more effective than their European colleagues, while Portuguese 
practitioners regarding refractive surgery as a more effective technique for myopia control 
than their European colleagues (p < 0.001). Russian practitioners perceived pharmaceutical 
methods as less effective than other European practitioners, while Italian practitioners and 
those from the UK/EIRE thought increased time spent outdoors was less effective at slowing 
myopia that other European practitioners (p < 0.001).  Within North America, practitioners 
from the USA perceived rigid gas permeable (RGP) and multifocal soft contact lenses, as 
well as orthokeratology and pharmaceutical options, as more effective than their Canadian 
counterparts (p < 0.001). 
 
 Continent  













Under-correction 11.6 ± 21.6 0.2 ± 6.6 6.9 ± 17.6 1.4 ± 4.6 14.9 ± 2 1.9 
Single Vision   17.6 ± 24.9 1.2 ± 3.8 13.4 ± 24.7 1.2 ± 3.7 21.3 ± 32.9 
Bifocals 33.0 ± 22.7 25.4 ± 17.4 19.4 ± 20.5 16.7 ± 15.1 16. 0 ± 22.2 
Progressive 
Addition (PALs) 









 Rigid G as 
Permeable (RGP) 
25.0 ± 27.8 8.4 ± 16.3 16.8 ± 24.1 6.8 ± 12.7 15.0 ± 25.1 
Single Vision Soft 18.1 ± 24.6 3.1 ± 10.3 13.1 ± 21.9 1.7 ± 4.5 16.3 ±  27.1 
Multifocal Soft 31.9 ± 23.6 35.7 ± 18.0 26.6 ± 22.5 31.4 ± 19.0 21. 9 ± 26.6 
Approved Myopia 
Control Soft 
45.4 ± 24.0 45.6 ± 18.2 44.1 ± 24.4 42.9 ± 20.0 29. 0 ± 29.4 
Orthokeratology 60.7 ± 21.9 52.5 ± 21.2 52.1 ± 24.7 48.3 ± 22.0 34. 8 ± 31.1 
  Pharmaceutical 54.5 ± 23.6 52.1 ± 20.9 43.1 ± 26.9 45.6 ± 21.3 43. 0 ± 29.8 
  Refractive Surgery 20.6 ± 33.0 7.7 ± 21.3 13.9 ± 25.6 8.1 ± 22.2 13.9 ± 24.8 
  Increased Time 
Outdoors  43.6 ± 27.8 20.4 ± 20.5 37.1 ± 27.7 22.4 ± 20.1 40. 2 ± 31.8 
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Table 1:  Perceived effectiveness (defined as the expected level of reduction in 
childhood myopia progression in percent) of myopia control options by 
practitioners in different continents. Data are expressed as mean ± S.D. 
 
Perceived level of clinical activity in the area of myopia control (Figure 2) 
Practitioners from Asia considered their clinical practice of myopia control to be the most 
active (7.7 ± 2.3; p < 0.001) among the surveyed continents, with similar levels for 
Australasia (7.3 ± 2.5; p < 0.001) and Europe (7.0 ± 4.2; p < 0.001), and least by 
practitioners from North America (6.3 ± 2.9; p < 0.001) and South America (6.4 ± 3.2; p < 
0.001). North American practitioners perceived themselves to be the least active in this area 
of practice (p < 0.001). Within Europe, practitioners from Russia (8.5 ± 9.8; p < 0.001) 
reported the highest perceived level of clinical activity in myopia control and the lowest was 
reported by those from the UK/EIRE (6.1 ± 3.5; p < 0.001), with similar responses by Spain 
(7.0 ± 2.6; p < 0.001), Italy (7.0 ± 2.3; p < 0.001), Portugal (6.6 ± 2.5; p < 0.001), the 
Netherlands (6.6 ± 2.6; p < 0.001), and Germany (6.6 ± 3.0; p < 0.001). Within Asia, Indian 
practitioners (6.3 ± 2.6; p < 0.001) considered themselves relatively less active than their 
counterparts in China (8.4 ± 2.2; p < 0.001) or Hong Kong (8.1 ± 2.0; p < 0.001). Within 
North America, Canadian practitioners (5.7 ± 3.0; p < 0.001) considered themselves less 
active than those from the USA (6.6 ± 2.8; p < 0.001). 
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Figure 2:  Perceived level of clinical activity in the area of myopia control for practitioners 
located in different continents. N=1,336. Box = 1 SD, line = median and 
whiskers 95% confidence interval. 
 
Frequency of prescribing different myopia correction options for progressing / young myopes 
(Table 2) 
The majority of progressing / young myopes were being prescribed single vision (full 
correction) spectacles (39.3 ± 30.0%), followed by single vision soft contact lenses (12.3 ± 
15.5%) and orthokeratology (12.0 ± 20.0%). The least frequently prescribed myopia 
correction option was refractive surgery (0.8 ± 4.1%), followed by rigid gas permeable (RGP) 
contact lenses (2.1 ± 6.6%) and bifocal spectacles (2.4 ± 6.2%). Progressive addition (PALs) 
spectacles (8.8 ± 14.5%), multifocal soft contact lenses (6.8 ± 13.9%), approved myopia 
control soft contact lenses (7.3 ± 13.0%), and pharmaceutical options were prescribed at a 
similar frequency (8.2 ± 16.3%). These findings were largely consistent across all continents 
with some variations. Practitioners from Asia indicated prescribing single vision (full 
correction) spectacles most frequently, whereas those from Australasia prescribed them 
least often (p < 0.001). Also, practitioners from Asia indicated prescribing bifocal spectacles 
most frequently for progressing / young myopes, whereas those from South America 
prescribed them least often (p < 0.001). Practitioners from Australasia, and to a lesser 
degree, practitioners from Asia, prescribed progressive addition (PALs) spectacles more 
frequently than those from other continents, while the option was prescribed least often by 
South America (p < 0.001). South American practitioners prescribed conventional rigid gas 
permeable (RGP) contact lenses most frequently to these patients, while was done least 
often by their counterparts in Australasia (p < 0.001). Practitioners from North America and 
Australasia prescribed more single vision and multifocal soft contact lenses respectively, 
while Asian practitioners prescribed these options less often than other regions (p < 0.001). 
Approved myopia control soft contact lenses are being prescribed most in Australasia, 
Europe, and North America, while notably less in Asia and South America (p < 0.001). 
Practitioners from Australasia, and to a lesser degree, practitioners from Europe, prescribed 
orthokeratology more frequently than their counterparts, while this option was prescribed 
least frequently by South American practitioners (p < 0.001). South American practitioners 
indicated utilising pharmaceutical options notably most frequently for progressing / young 
myopes, while those from Asia and Europe did so the least (p < 0.001). South American 
practitioners also recommended refractive surgery more than other continents for these 
patients, but the prescribing frequency was still low (p < 0.001).  
 
Within Asia, practitioners from India prescribed single vision spectacles, rigid gas permeable 
(RGP), single vision, multifocal, and approved myopia control soft contact lenses, as well as 
pharmaceutical myopia correction options most frequently (p < 0.001). Chinese practitioners 
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prescribed progressive addition (PALs) spectacles the most frequently and orthokeratology 
the least in comparison to Hong Kong and India (p < 0.001). Within Europe, practitioners 
from Russia and Spain prescribed single vision spectacles and soft contact lenses most 
frequently, whereas practitioners from the Netherlands prescribed these options the least (p 
< 0.001). Russian practitioners also prescribed bifocal and progressive addition (PALs) 
spectacles the most, whereas their colleagues from the Netherlands and Portugal did so the 
least (p < 0.001). German practitioners prescribed rigid gas permeable (RGP) and multifocal 
soft contact lenses most frequently, whereas those from the UK/EIRE and Portugal 
prescribed these options the least (p < 0.001). Spanish practitioners demonstrated the 
highest frequency of prescribing approved myopia control soft contact lenses (p < 0.001). 
Orthokeratology was prescribed the most in Italy and the Netherlands, and the least by 
Portuguese practitioners (p < 0.001). Russian practitioners had the highest frequency of 
prescribing pharmaceutical and refractive surgery options (p < 0.001). Within North America, 
practitioners from the USA prescribed single vision spectacles and soft contact lenses more 
frequently than their Canadian colleagues (p < 0.001).       
 
Continent   













Single Vision   54.7 ± 31.9 18.8 ± 22.3 37.3 ± 29.3 36.5 ± 30.5 49. 3 ± 35.8 
Bifocals 3.4 ± 7.7 2.8 ± 6.2 2.0 ± 7.5 2.6 ± 5.7 1.1 ± 4.0 
Progressive 
Addition (PALs) 









 Rigid G as 
Permeable (RGP) 
1.8 ± 4.7 0.3 ± 1.1 2.9 ± 9.6 1.1 ± 9.1 4.5 ± 8.4 
Single Vision Soft 7.2 ± 13.0 9.6 ± 13.3 15.6 ± 17.3 16.6 ± 19.0 12.4 ± 14.8 
Multifocal Soft 1.7 ± 5.1 13.0 ± 18.5 5.5 ± 13.7 8.2 ± 15.5 5.6 ± 1 6.7 
Approved  Myopia 
Control Soft 
3.6 ± 8.7 10.5 ± 14.9 10.5 ± 16.9 9.6 ± 16.4 2.2 ± 8.3 
Orthokeratology 11.5 ± 20.4 16.8 ± 22.0 15.9 ± 24.4 12.3 ± 19.4 3.3  ± 11.8 
  Pharmaceutical 4.1 ± 11.9 8.7 ± 11.7 4.7 ± 15.0 7.2 ± 12.1 16.3 ± 30.7 
  Refractive Surgery 0.9 ± 4.1 0.1 ± 0.6 1.0 ± 6.7 0.4 ± 2.9 1.7 ± 6.3 
Table 2:  Frequency of prescribing myopia correction options (in percent) for 
progressing / young myopes by practitioners in different continents for 
progressing / young myopes. Data are expressed as mean ± S.D. 
 
Minimum patient age that practitioners consider myopia correction options (Table 3) 
Overall, single vision spectacles were prescribed from the youngest age (6.8 ± 4.2 years), 
whereas rigid gas permeable (RGP) contact lenses were reserved for older children (13.3 ± 
5.3). Bifocal spectacles (8.9 ± 5.7), progressive addition (PALs) spectacles (8.9 ± 6.0), single 
vision soft contact lenses (9.0 ± 4.8), multifocal soft contact lenses (10.2 ± 4.9), specific 
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myopia control soft contact lenses (8.9 ± 4.0), orthokeratology (9.7 ± 4.8), and 
pharmaceutical (9.6 ± 6.0) options were all prescribed for a similar minimum patient age 
range. Practitioners from all regions generally did not recommend refractive surgery to 
patients under 18 years of age (19.6 ± 1.6). Practitioners from Asia, Australasia, and North 
America were more conservative in their minimum fitting age of rigid gas permeable (RGP) 
contact lenses than European and South American practitioners (p < 0.001). Practitioners 
from Asia were most conservative in their minimum patient age for prescribing single vision, 
multifocal, and specific myopia control soft contact lenses (p < 0.001). South American 
practitioners tended to be least conservative towards most myopia correction options relative 
to their colleagues (p < 0.001).   
 
Within Asia, practitioners from Hong Kong were the most conservative in their minimum age 
for fitting rigid gas permeable (RGP), single vision and multifocal soft contact lenses, as well 
as pharmaceuticals (p < 0.001). Practitioners from India were the most conservative in fitting 
bifocal and progressive addition (PALs) spectacles, as well as orthokeratology (p < 0.001). 
Chinese practitioners were least conservative in prescribing bifocal spectacles, multifocal 
soft contact lenses, and pharmaceutical options (p < 0.001). Within Europe, practitioners 
from the Netherlands were the most conservative in their minimum age for fitting most of the 
myopia correction options, followed by the UK/EIRE, particularly for bifocal and progressive 
addition (PALs) spectacles, rigid gas permeable (RGP) contact lenses, as well as 
orthokeratology, pharmaceutical, and refractive surgery (p < 0.001). Within North America, 
Canadian practitioners were more conservative regarding bifocal spectacles and 




Continent   













Single Vision   7.0 ± 4.4 (1) 8.0 ± 6.0 6.0 ± 3.2 (8) 7.7 ± 5.9 5.5  ± 1.7 (16) 
Bifocals 10.4 ± 6.5 (12) 9.5 ± 6.9 9.0 ± 6.1 (38) 9.6 ± 7.0 5.9 ± 2.1 (66) 
Progressive 
Addition (PALs) 









 Rigid G as 
Permeable (RGP) 
15.2 ± 5.6 (9) 15.4 ± 6.2 10.8 ± 4.8 (36) 14.2 ± 6. 2 10.9 ± 3.9 (42) 
Single Vision Soft 13.2 ± 5.2 (10) 11.1 ± 5.8 9.0 ± 3.9 (12) 10.4 ± 5. 3 10.2 ± 3.9 (28) 
Multifocal Soft 13.8 ± 5.9 (15) 9.9 ± 5.2 9.3 ± 4.5 (33) 9.4 ± 4.9 8.8 ± 4.1 (61) 
Specific Myopia 
Control Soft 
10.8 ± 4.8 (10) 8.5 ± 3.9 7.8 ± 3.2 (7) 8.3 ± 3.9 9 .2 ± 4.2 (36) 
Orthokeratology 9.8 ± 5.1 (10) 9.6 ± 5.0 9.3 ± 4.0 (11) 10.7 ± 6.1 9.1 ± 4.2 (44) 
  Pharmaceutical 13.0 ± 7.6 (13) 8.5 ± 5.8 10.6 ± 6.9 (53) 9.5 ± 6.5  6.5 ± 3.2 (35) 
  Refractive Surgery 19.9 ± 2.1 (22) 20.4 ± 1.2 19.3 ± 2.7 (71) 20.4 ± 1 .2 18.2 ± 0.9 (71) 
Table 3:  Minimum patient age considered necessary by practitioners (from different 
continents) who prescribed these options for different myopia correction 
options. Data are expressed as mean ± S.D years (% that would not prescribe 
this refractive modality – no practitioners stated this to be the case with any 
refractive correction in Australasia or North America). 
 
Minimum degree of myopia that needs to be present for practitioners to consider myopia 
control options (Table 4) 
Overall, practitioners indicated that myopia would be corrected with single vision spectacles 
at the lowest degree of myopia (-0.82 ± 0.58 D), whereas it would be corrected with 
refractive surgery at the highest degree (-2.80 ± 1.72 D). All other myopia control options 
would be considered at approximately -1.50 D, except for rigid gas permeable (RGP) contact 
lenses that were considered at -2.50 D. Australasian and North American practitioners were 
willing to fit most modalities at a lower level of myopia than Asian, European or South 
American clinicians (p < 0.001). South American practitioners required a higher level of 
myopic refractive error before they would consider bifocal spectacles, multifocal soft contact 
lenses, and orthokeratology than all other regions (p < 0.001). Asian practitioners prescribed 
rigid gas permeable (RGP) and single vision soft contact lenses, as well as refractive 
surgery to children with a higher degree of myopia than others (p < 0.001). However, North 
American practitioners considered rigid gas permeable (RGP) contact lenses at a lower level 
of myopia than in other continents (p < 0.001). Practitioners from Asia and South America 
recommended approved myopia control soft contact lenses and pharmaceutical options at 
higher levels of myopia (p < 0.001). 
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Within Asia, Indian practitioners required a higher level of refractive error before they would 
consider bifocal and progressive addition (PALs) spectacles, as well as orthokeratology, 
pharmaceutical and refractive surgery options (p < 0.001) than practitioners from China or 
Hong Kong. Within Europe, Portuguese practitioners considered single vision, bifocal and 
progressive addition (PALs) spectacles, rigid gas permeable (RGP) and approved myopia 
control soft contact lenses, orthokeratology, pharmaceutical, and refractive surgery options 
for a higher myopia level than other countries in the continent (p < 0.001). Spanish 
practitioners also required a higher level of myopia for approved myopia control soft contact 
lenses and pharmaceuticals, as well as multifocal soft contact lenses (p < 0.001). Italian 
practitioners required high myopia levels when considering refractive surgery (p < 0.001). 
Practitioners from Russia required a higher level of myopia before utilising single vision soft 
contact lenses, but lower levels for pharmaceuticals relative to their European colleagues (p 
< 0.001). Practitioners from the UK/EIRE considered single vision, bifocal and progressive 
addition (PALs) spectacles, single vision, multifocal and approved myopia control soft 
contact lenses, and refractive surgery options for a lower myopia level than others in the 
continent (p < 0.001). German practitioners also required a lower level of myopia for single 
vision, bifocal and progressive addition (PALs) spectacles, as well as rigid gas permeable 
(RGP) and single vision soft contact lenses (p < 0.001). The same was reported by 
practitioners from the Netherlands regarding single vision and bifocal spectacles, and rigid 
gas permeable (RGP) and single vision soft contact lenses (p < 0.001). The only difference 
across North America was that Canadian practitioners required a higher level of myopia 
before they would consider rigid gas permeable (RGP) contact lenses than those from the 




Continent   













Single Vision   -1.0 ± 0.9 -0.6 ± 0.2 -0.9 ± 0.7 -0.7 ± 0.4 -0.9 ± 0.7 
Bifocals -1.8 ± 1.4 -0.9 ± 0.4 -1.8 ± 1.3 -1.2 ± 1.0 -2.3 ± 1.7 
Progressive 
Addition (PALs) 









 Rigid G as 
Permeable (RGP) 
-2.9 ± 2.0 -2.5 ± 2.1 -2.4 ± 2.0 -2.0 ± 1.6 -2.7 ± 2.1 
Single Vision Soft -1.8 ± 1.4 -1.0 ± 0.4 -1.3 ± 0.9 -1.0 ± 0.5 -1.5 ± 1.2 
Multifocal Soft -1.7 ± 1.2 -1.0 ± 0.4 -1.6 ± 1.3 -1.2 ± 0.7 -1.9 ± 1.6 
Approved Myopia 
Control Soft 
-1.8 ± 1.5 -1.0 ± 0.4 -1.5 ± 1.1 -1.2 ± 0.7 -1.9 ± 1.6 
Orthokeratology -1.7 ± 1.3 -1.3 ± 0.7 -1.6 ± 1.0 -1.3 ± 0.7 -2.1 ± 1.6 
  Pharmaceutical -1.9 ± 1.8 -1.2 ± 0.5 -1.5 ± 1.3 -1.3 ± 1.0 -1.9 ± 1.2 
  Refractive Surgery -3.8 ± 2.4 -2.2 ± 1.0 -3.3 ± 2.3 -2.0 ± 1.2 -2.7 ± 1.7 
Table 4:  Minimum level of patient myopia (in dioptres) before myopia correction 
options would be considered by practitioners from different continents who 
prescribed these options. Data are expressed as mean ± S.D. 
 
Minimum annual amount of patient myopia progression that would prompt a practitioner to 
specifically adopt a myopia control approach (Figure 3) 
The minimum myopia progression rate that practitioners considered warranted a myopia 
control approach was 0.51 to 0.75 D/year for the majority of respondents (36.7%), with 82% 
indicating a level between 0.25 and 1.00 D/year. Practitioners from Australasia indicated 
they would adopt myopia control strategies for the lowest level of myopia progression, 
followed by Europe and North America (p < 0.001). Highest rates of progression were 
required in South America, followed by Asia (p < 0.001). Practitioners from Australasia, 
Europe, and North America particularly indicated a range between 0.26 and 0.75 D/year of 
patient myopia progression that would prompt the adaptation of a myopia control approach. 
In comparison, the range increased to between 0.26 and 1.00 D/year for Asian practitioners 
and spread further between 0.26 and > 1.00 D/year among South American practitioners (p 
< 0.001). Other factors influencing practitioners’ management decisions, as identified from 
the free text responses, included ethnicity (1 respondent), absolute degree of refractive error 
at the time (2 respondents), environmental factors/lifestyle (2 respondents), lighting 
exposure (2 respondents), parental decisions (2 respondents), ocular biometry (3 





Figure 3:  Minimum annual amount of patient myopia progression, in dioptres per year 
(D/year), that practitioners located in different continents considered to 
necessitate a myopia control approach. N=1,336  
 
Use of single-vision under-correction as a strategy to slow myopia progression (Figure 4) 
Overall, most practitioners did not consider single-vision distance under-correction to be an 
effective strategy for attenuating myopia progression (79.6%). South American practitioners 
used this strategy relatively more than all other regions (p < 0.001). Within Asia, Indian 
practitioners utilised under-correction more than those from China or Hong Kong (p < 0.001). 
Within Europe, practitioners from Portugal, Russia, and Spain indicated using under-
correction as a strategy to control myopia more than their counterparts (p < 0.001). Within 
North America, there was no difference in the use of under-correction between Canada and 
the USA (p = 0.999).  
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Figure 4:  Use of single-vision distance under-correction as a strategy to slow myopia 
progression by practitioners located in different continents. N=1,336.  
 
Factors preventing the prescription of a myopia control approach (Figure 5) 
The most common reasons practitioners gave for not adopting myopia control strategies 
were: they were felt to be uneconomical (20.6%); they considered there to be inadequate 
information about the modalities (17.6%); they viewed the outcomes to be unpredictable 
(9.6%); concerns about safety (8.5%); they perceived them to be ineffective for reducing 
myopia progression (7.9%); the benefit to risk ratio was too low (7.0%); and additional chair 
time (3.1%). There was no significant difference in the distribution of these factors between 
or within continents (p > 0.05). Free text comments identified other factors affecting the 
prescription of these strategies to relate to the relative availability of the myopia control 
treatments and the instrumentation necessary to prescribe them, and the need for consistent 
regulations and informational materials.  
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Figure 5:  Factors preventing practitioners located in different continents from 





This report updates a study from 2015 [12] that examined the self-reported attitudes and 
practices of eye care practitioners towards myopia control approaches across the globe. 
More than one thousand practitioners responded, principally spread over five continents. 
The exact response rate is not known, as maximum coverage was promoted by involving 
professional bodies whose members may not all be practicing eye care practitioners. 
However, it may be presumed that questionnaires are completed both by people cynical and 
enthusiastic to the issue being examined, balancing the average response. In addition, the 
recruitment approach across nations was the same, allowing cross-national comparisons. 
The majority of the respondents (92.1%) were again (91% in 2015)[16] optometrists and 
ophthalmologists, reflecting those professions legally allowed to prescribe vision care 
correction and, in many regions, pharmaceuticals as well.  
 
Once again, as one might expect from the high prevalence rates of myopia in Asia, Asian 
practitioners, especially those practicing in China, were more concerned about the 
increasing prevalence of paediatric myopia in their practices than clinicians in any of the 
other continents. A similar pattern existed in relation to how active they considered their 
clinical practice in the area of myopia control. Data collected over the last decade on myopia 
prevalence suggests it is approximately 30% in 30-35 year olds in Spain [13] and may be 
increasing in Portugal,[14] but is as high as 58% in Italian university students, and as low as 
23% in 12-13 year olds in the UK [15] and 28% in Dutch school children;[16] hence it is 
unclear why the former two country’s practitioners are more concerned than the latter two. 
The prevalence of myopia in the USA is around 42% in 12-54 year olds [17] and around 29% 
in 11 to 13 year olds in Canada [18] which might explain their lower concern. The myopia 
occurrence is not documented in Russia or Germany to warrant their higher and lower 
concern in Europe respectively. 
 
Overall, orthokeratology was again perceived by practitioners to be the most effective 
method of myopia control (24-49% retardation of myopia in 2015 versus 35-61% in 2019 
across the continents). However, in this survey update, eye care practitioners’ correctly 
perceived pharmaceutical approaches and approved myopia control soft contact lenses to 
be similarly effective, in accordance with the IMI white paper by Wildsoet et al.[6] 
Pharmaceutical approaches were not broken down into different drugs and concentrations, 
which might be informative for future surveys due to the differences in efficacy, mismatch 
between axial length and refractive error progression and rebound effect.[6] While single 
vision distance under-correction has been shown fairly conclusively to increase, rather than 
decrease, the rate of myopia progression in children,[19,20] there were still practitioners who 
consider the converse to be true; this was confirmed by a question later in the survey, with 
under-correction still practiced as a method of myopia control, particularly by practitioners 
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from South America, Portugal, Russia and Spain within Europe and India within Asia; 
however the reported use of undercorrection as a strategy for myopia control has decreased 
from the original survey (27.3% of practitioners used undercorrection at least some of the 
time in 2015 versus 20.4% in 2019.[12] 
 
Despite the self-perceived activity of practitioners in the area of myopia control, still over half 
of progressing and/or young myopes were being prescribed single vision spectacles or 
contact lenses (52%), with continental and national differences in the adoption of refractive 
correction options known to reduce myopia progression. However, this is an improvement in 
comparison to the reported 68% from the original study four years ago.[12] Strangely, there 
are still some practitioners who believe refractive surgery is a suitable management for 
young, progressing myopes, especially in South America! Approximately one third of 
practitioners not adopting myopia control approaches felt them to be uneconomical and/or 
that there was inadequate information about them; about another one third of respondents 
suggested that outcomes were unpredictable, the relative safety of these strategies was 
concerning, myopia control methods were ineffective and/or that the benefit to risk ratio was 
too low; with some also mentioning the involved additional chair time. Further comments 
raised the issue of availability of some myopia control options, presumably of novel myopia 
control lenses, as current approaches are off-label, highlighting the need for regulatory 
oversight and guidance.[8] Limited access to necessary instrumentation was also raised as a 
potential barrier, as more advanced contact lens fitting, such as orthokeratology, require the 
use of corneal topography.[9] Attempts to specifically manipulate peripheral retinal focus of 
an individual may also require instrumentation to rapidly and robustly assess peripheral 
retinal shape, axial length and/or refraction with myopia control ophthalmic medical 
devices.[7] However, this strategy might not ‘translate’ well from animal studies to human 
trials.[21,22] 
 
Spherical equivalent refractive error (measured under cycloplegia) is currently the single 
best predictive measure of juvenile myopia development, with children aged six years with 
less than +0.75D of hyperopia being at increased risk of developing myopia (Zadnik et al., 
2015). Most practitioners were again comfortable fitting single vision spectacles to myopic 
patients of this age, but in this update tended to wait until a child was older for single vision 
soft contact lenses and pharmaceuticals in addition to the more complex designs such as 
PALs, novel myopia control soft contact lenses and orthokeratology RGPs compared to that 
reported in 2015.[12] Interestingly, one potential advantage of orthokeratology is that the 
parents or carer can manage lens application, removal and lens care, along with the lenses 
not having to leave the home, which can make this modality a popular option for parents or 
carers with younger myopic children. This is exemplified by Hong Kong, an early adopter of 
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orthokeratology, where its use is considered at an earlier age than other countries in the 
region.  
 
Research suggests that lower levels of hypermetropia at a young age is a strong risk factor 
for myopia development,[23] so it would seem that practitioners remain too conservative in 
waiting until mild-moderate levels of myopia (approximately -1.50 D for most interventions) 
are present before control approaches are considered.[21,23] However, this is an 
improvement in comparison to the reported -2.00 D minimum degree of myopia from the 
original study four years ago.[12] Some optical treatments such as orthokeratology are more 
effective for mild levels of myopia,[24] so this may affect practitioner thinking. Myopia 
progresses at much faster rates in children in comparison to teenagers, thus supporting the 
need for earlier intervention.[25] There may be also a “window of opportunity” for myopia 
treatment according to the age of onset, rate of progression and myopia magnitude.[26] 
More research is needed on the relative benefits of myopia control strategies in adolescents 
and even young adults. Interestingly, Australasian and North American practitioners, but not 
those from Asia this time, considered most myopia control approaches at a lower level of 
myopia than other continents. Chinese practitioners still considered prescribing 
pharmaceutical modalities at a younger age, and at a much lower level of myopia, compared 
with practitioners from other countries in the region. This may be due to different countries 
having different regulations and practitioners with different backgrounds (for example 
training, education and scope of practice), which can affect local practice habits, irrespective 
of the prevalence of myopia and need for correction or retardation. The rate of patient 
refractive progression that triggered practitioners to prescribe a myopia control approach 
generally mirrored the prevalence rate of myopia in each region; for example in Asia, myopia 
progression needs to be greater for a practitioner to commence myopia control treatments. 
The higher the prevalence of myopia, generally the higher the level of myopic refractive error 
developed in individuals and the subsequent higher risk of ocular pathology.27] Practitioners 
understandably also identified several other factors that, combined with the degree of 
myopic progression, influenced their decision to prescribe myopia control approaches; these 
included ethnicity, absolute degree of refractive error at the time, environmental 
factors/lifestyle, lighting exposure, parental decisions, ocular biometry, family history of 
myopia, and the age of myopia onset.  
 
In conclusion, this updated global survey of current trends in eye care practitioner myopia 
management attitudes and strategies in clinical practice has identified that, despite growing 
evidence of the negative impact of even low levels of myopia on health economics, and 
moderate levels of practitioner concern and perceived activity (particularly where the 
prevalence of myopia is highest) uptake of appropriate techniques has improved, but 
remains generally poor. Furthermore, myopia control techniques are not being applied early 
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enough in a child’s ocular development to elicit their optimum effect. Adequate education of 
practitioners is lacking, along with access to appropriately regulated myopia control ‘labelled’ 
products with efficacy and safety data. The recent IMI white papers provide a global 
evidence-based consensus to inform practitioners of models of eye care, including the 
development of instrumentation to enhance management selection, which address the 
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